openPR Logo
Press release

Wet Age-Related Macular Degeneration Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Is

04-11-2025 07:02 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Wet Age-Related Macular Degeneration Market

Wet Age-Related Macular Degeneration Market

DelveInsight's "Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Wet Age-Related Macular Degeneration Market Share @ Wet Age-Related Macular Degeneration Market Outlook- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Wet Age-Related Macular Degeneration Market Report
• In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023.
• The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases).
• Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM.
• Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023.
• The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases).
• Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM.
• In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand).
• The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR.
• The leading Wet Age-Related Macular Degeneration Companies such as Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others.

Stay ahead in the Wet Age-Related Macular Degeneration Therapeutics Market with DelveInsight's Strategic Report @ Wet Age-Related Macular Degeneration Market Outlook- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM
The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Prevalence- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wet Age-Related Macular Degeneration Marketed Drugs
• BEOVU (Brolucizumab): Novartis
BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules.

• EYLEA (aflibercept): Regeneron Pharmaceuticals
EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials.

• VABYSMO (faricimab): Roche/ Genentech, Inc.
VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels.

Wet Age-Related Macular Degeneration Emerging Drugs
• OPT-302: Opthea Limited
OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies.

• KSI-501: Kodiak Sciences Inc.
KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.

To learn more about Wet Age-Related Macular Degeneration treatment guidelines, visit @ Wet Age-Related Macular Degeneration Treatment Market Landscape- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wet Age-Related Macular Degeneration Market Outlook
Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients.

Wet Age-Related Macular Degeneration Drugs Uptake
The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration.

Major Wet Age-Related Macular Degeneration Companies
Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.

Learn more about the FDA-approved drugs for Wet Age-Related Macular Degeneration @ Drugs for Wet Age-Related Macular Degeneration Treatment- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Wet Age-Related Macular Degeneration Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Wet Age-Related Macular Degeneration Companies- Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others.
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers
• Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Report Introduction
3 Wet AMD Market Overview at a Glance
4 Wet AMD Market: Future Perspective
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs of Wet AMD
12 Wet AMD: Market Analysis
13 Key Opinion Leaders' Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Urea Cycle Disorders Market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Intraocular Lens Market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/blog/cardiac-monitoring-devices-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Wet Age-Related Macular Degeneration Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Is here

News-ID: 3966350 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Wet

Wet And Cold Appliance Market Size Analysis by Application, Type, and Region: Fo …
USA, New Jersey- According to Market Research Intellect, the global Wet And Cold Appliance market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The wet and cold appliance market is expanding steadily, driven by changing consumer lifestyles, increasing urbanization, and rising demand for home automation. Appliances
Semiconductor Electronic Wet Chemicals Market
Semiconductor Electronic Wet Chemicals Market Overview Electronic wet chemicals are ultra-pure nature due to which they are extensively used in cleaning and etching application during semiconductor production and processing. This report provides a deep insight into the global Semiconductor Electronic Wet Chemicals market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market
Global Wet Suit Market Analysis (2025-2031)
LPI (LP Information) released the report titled "Global Wet Suit Market Growth (Status and Outlook) 2025-2031." This report provides a comprehensive analysis of the global Wet Suit landscape, with a focus on key trends related to product segmentation, company establishment, revenue and market share, recent developments, and merger and acquisition activities. Additionally, the report delves into the strategies of global leading companies, emphasizing their Wet Suit portfolios and capabilities, market
Wet and Dry Vacuum Cleaner Market
The "Wet and Dry Vacuum Cleaner Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031.  The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Wet and Dry Vacuum Cleaner Market, 2024-2031 Verified Market Research's most recent report, "Wet and Dry Vacuum Cleaner Market: Global Industry Trends, Share, Size,
Wet Filtered Downdraught Workbench Market
Wet filtered downdraught workbench is the industry's leading solution for the collection of combustible metal dust which can safely removes combustible materials while complying with NFPA and OSHA combustible dust guidelines. The global Wet Filtered Downdraught Workbench market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine
Corn Wet-milling Market Corn Wet Milling Market Share, Size, Demand, Key Players …
Market Analysis and Insights of Global Corn Wet-milling Market The corn wet-milling market is expected to witness market growth at a rate of 5.70% in the forecast period of 2022 to 2029. Data Bridge Market Research report on corn wet-milling market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The growth in awareness globally is